Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.

Abstract

Clinical stage III melanoma, defined as resectable RECIST measurable nodal disease with or without in-transit metastases, represents approximately 15% of new melanoma diagnoses every year with additional cases presenting as recurrent nodal disease following previous treatment of a primary melanoma. The standard of care for patients with resectable clinical stage III melanoma is surgical resection, consisting of therapeutic lymph node dissection and/or resection of in-transit disease and consideration of adjuvant systemic therapy and occasionally adjuvant radiation. These patients have high rates of regional recurrence and progression to metastatic disease postsurgery, highlighting the need for better treatment options. With the success of immune checkpoint inhibitors in both the adjuvant and metastatic settings, the use of these agents in the neoadjuvant setting has been an emerging area of research interest. In this chapter, we will discuss the rationale for neoadjuvant immunotherapy; review impactful clinical trials; and define response monitoring, surgical considerations, emerging therapies, and unanswered questions for neoadjuvant therapy as a recent paradigm shift in the management of clinical stage III melanoma.

• Authors: Tina J Hieken, Firas Kreidieh, Veronica Aedo-Lopez, Matthew S Block, Grant A McArthur, Rodabe N Amaria
• Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (Am Soc Clin Oncol Educ Book) Vol. 43 Pg. e390614 (Jan 2023) ISSN: 1548-8756 [Electronic] United States
• PMID: 37116111 (Publication Type: Journal Article)

Topics

• Humans
• Neoadjuvant Therapy
• Melanoma (drug therapy)
• Skin Neoplasms
• Immunotherapy
• Melanoma, Cutaneous Malignant